Table 1.
Baseline characteristics of the study population.
| Total (N = 325) | |
|---|---|
| Indication to start triptorelin treatment at baseline | |
| Neoadjuvant before radical prostatectomy | 5 (1.5%) |
| Neoadjuvant before radiotherapy or brachytherapy | 62 (19.1%) |
| Adjuvant after radical prostatectomy | 12 (3.7%) |
| Adjuvant after radiotherapy or brachytherapy | 4 (1.2%) |
| Rising PSA after radical prostatectomy | 29 (8.9%) |
| Rising PSA after radiotherapy or brachytherapy | 23 (7.1%) |
| Locally advanced, first line therapy | 135 (41.5%) |
| Locally advanced, after antiandrogen therapy | 7 (2.2%) |
| Metastatic, first line therapy | 43 (13.2%) |
| Other | 17 (5.2%) |
| Missing data | 0 |
| Age at first prostate cancer diagnosis (years) | |
| Mean (SD) | 72.86 (8.26) |
| TNM staging: T | |
| T1 | 10 (3.1%) |
| T1 | 1 (0.3%) |
| T1a | 1 (0.3%) |
| T1b | 3 (0.9%) |
| T1c | 5 (1.6%) |
| T2 | 47 (14.7%) |
| T2 | 26 (8.1%) |
| T2a | 7 (2.2%) |
| T2b | 9 (2.8%) |
| T2c | 5 (1.6%) |
| T3 | 241 (75.1%) |
| T3 | 182 (56.7%) |
| T3a | 43 (13.4%) |
| T3b | 16 (5.0%) |
| T4 | 22 (6.9%) |
| TX | 1 (0.3%) |
| Missing data | 4 |
| TNM staging: N | |
| N0 | 178 (57.1%) |
| N1 | 43 (13.8%) |
| NX | 91 (29.2%) |
| Missing data | 13 |
| TNM staging: M | |
| M0 | 199 (63.4%) |
| M1 | 35 (11.1%) |
| M1 | 28 (8.9%) |
| M1a | 1 (0.3%) |
| M1b | 6 (1.9%) |
| MX | 80 (25.5%) |
| Missing data | 11 |
| Gleason score | |
| ≤6 | 106 (35.5%) |
| 7 | 99 (33.1%) |
| ≥8 | 94 (31.4%) |
| Missing data | 26 |